undamentalytics Newsletter
Sign in

Kalaris Therapeutics, Inc. (KLRS) stock

Add to watchlist

Add holding +

NASDAQ: KLRS Nasdaq Biotechnology Next results ~November 11, 2026

Kalaris Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.5

Forward price-to-sales vs peers

Base case. Range ~$1.5–$5.7. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Kalaris Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling2 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds28 adding, 20 cuttingOf 12 active managers that changed their stake, 6 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Kalaris Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 85% and a beta of 0.8 against the S&P 500.

Latest results

Earnings per share
-$0.48 against an average estimate of -$0.49: beat by 3.0%
Share reaction
0.0% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500

Kalaris Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.5%
  • 1 week+11.1%
  • 1 month-25.9%
  • This year-76.3%
  • 1 year-60.2%
  • 5 years-99.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Announcement
  4. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kalaris Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Kalaris Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.5 ~$1.5–$5.7 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.5 ~$1.5–$5.7 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kalaris Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.00 +30% — 0%
Next −$1.65 +17% $11m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.2% on 90 days ago. In the last 30 days, 5 analysts raised Kalaris Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Kalaris Therapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.03 Current fiscal year, 60 days ago: −$2.01 Current fiscal year, 30 days ago: −$2.01 Current fiscal year, 7 days ago: −$2.00 Current fiscal year, Now: −$2.00 −$2.00 Next fiscal year, 90 days ago: −$1.63 Next fiscal year, 60 days ago: −$1.66 Next fiscal year, 30 days ago: −$1.66 Next fiscal year, 7 days ago: −$1.65 Next fiscal year, Now: −$1.65 −$1.65

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.03−$1.63
60 days ago −$2.01−$1.66
30 days ago −$2.01−$1.66
7 days ago −$2.00−$1.65
Now −$2.00−$1.65

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.49 −$0.48 +3.0%
Mar 2026 −$0.52 −$0.46 +12.1%
Dec 2025 −$0.55 −$0.44 +20.0%
Sept 2025 −$0.61 −$0.64 −4.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold113%
Sell00%

Monthly trend

  1. Oct 20262518
  2. Sep 20262518
  3. Aug 20262518
  4. Jul 20262518

Counts of recommendations published by analysts covering Kalaris Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.7%
of tradable shares
Days to cover
3.69
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
82%
of shares
Held by insiders
8.8%
of shares
Employees
20
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KLRS−66%−60%−87%−38%−13%−76%
Industry peers (median)−35%−56%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KLRS25%50%33%67%50%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KLRS−72%−76%−90%−60%−80%−84%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since July 30, 2020: 100% from December 4, 2020 to October 26, 2026. Getting back needed a 59713% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.80 – $10.98
From 52-week high
−81.8%
vs 50-day average
−31.1%
vs 200-day average
−62.8%
Volatility (1 year)
85%
Beta vs S&P 500
0.85

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±7.9%
After a week
6 up, 6 down
typical move ±10.2%
After a month
6 up, 6 down
typical move ±28.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 0.0% −0.1% +2.3% −16.2%
May 12, 2026 +2.1% +0.4% −0.6% −7.8%
March 17, 2026 −14.5% −1.1% −29.6% −25.2%
November 12, 2025 +5.1% −1.6% +31.8% +75.0%
August 13, 2025 −8.8% +0.4% +3.2% +56.2%
May 14, 2025 +8.9% +0.6% −8.3% −18.8%
March 18, 2025 +18.7% 0.0% −8.7% −30.6%
November 2, 2023 +9.1% +2.8% −8.8% +36.4%
August 3, 2023 +3.0% −0.7% −2.3% +6.6%
May 4, 2023 +14.2% +1.1% +8.8% +15.5%
February 15, 2023 −6.1% −1.1% +7.1% −30.9%
January 9, 2023 +4.7% +0.6% +10.7% +17.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$73.4M
Institutions reporting
56
Shares held vs prior quarter
▼ 3.6%
Positions opened / closed
10 / 12

Top buyers and sellers, Q2 2026: 28 institutions bought and 20 sold ; the biggest buyer was UBS Group AG (+256K shares) and the biggest seller Paradigm Biocapital Advisors LP (−700K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Samsara Biocapital, LLC $52.4M 12.9M 71.4% ▼ 0.5%
RTW Investments, LP $5.3M 1.3M 7.2% 0.0%
Alyeska Investment Group, L.P. $2.3M 573K 3.2% 0.0%
Siren, L.L.C. $1.8M 436K 2.4% 0.0%
Vanguard Capital Management LLC $1.6M 399K 2.2% ▲ 56.1%
Ikarian Capital, LLC $1.5M 360K 2.0% 0.0%
UBS Group AG $1.1M 262K 1.5% ▲ 4138.9%
Renaissance Technologies LLC $607,859 149K 0.8% ▲ 125.8%
Marshall Wace, LLP $566,549 139K 0.8% ▲ 105.1%
Geode Capital Management, LLC $464,287 114K 0.6% ▲ 30.3%
ADAR1 Capital Management, LLC $407,000 100K 0.6% 0.0%
Woodline Partners LP $407,000 100K 0.6% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kalaris Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $6.2M 2 trades by 2 insiders, last 12 months Insider sales History → $12,869 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $6.2M net buying
Insider Date Trade Shares Price Value
Samsara Biocapital, L.P. 10% owner May 20, 2026 Buy 244,300 $4.83 $1.2M
Hagen Brett R Chief Accounting Officer March 20, 2026 Sell 1,915 $6.72 $12,869
Samsara Opportunity Fund, L.P. 10% owner December 18, 2025 Buy 479,847 $10.42 $5M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 17, 2026
  • November 12, 2025
  • August 13, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Kalaris Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kalaris Therapeutics, Inc. in brief

What does Kalaris Therapeutics, Inc. do?
Kalaris Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Kalaris Therapeutics, Inc.'s stock ticker?
Kalaris Therapeutics, Inc. trades under the ticker KLRS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Kalaris Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Samsara Biocapital, LLC, RTW Investments, LP and Alyeska Investment Group, L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Kalaris Therapeutics, Inc. stock?
Over the last 12 months, Kalaris Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Kalaris Therapeutics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kalaris Therapeutics, Inc. announces its own schedule.